Bradley A. Keywell Sells 170,720 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) major shareholder Bradley A. Keywell sold 170,720 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $35.45, for a total transaction of $6,052,024.00. Following the transaction, the insider now directly owns 15,993,729 shares in the company, valued at $566,977,693.05. The trade was a 1.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Tempus AI Stock Up 1.2 %

NASDAQ:TEM opened at $35.15 on Friday. The firm’s fifty day simple moving average is $46.03 and its 200-day simple moving average is $47.18. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $79.49.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. NEA Management Company LLC acquired a new stake in shares of Tempus AI during the 2nd quarter valued at approximately $160,048,000. Novo Holdings A S purchased a new position in Tempus AI in the 2nd quarter valued at approximately $142,605,000. ARK Investment Management LLC raised its holdings in Tempus AI by 355.0% during the third quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company’s stock worth $134,604,000 after purchasing an additional 1,855,459 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its holdings in Tempus AI by 1,591.2% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after purchasing an additional 1,145,698 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA acquired a new stake in Tempus AI in the second quarter valued at $28,246,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and set a $56.00 price target on shares of Tempus AI in a report on Tuesday, January 14th. Wolfe Research initiated coverage on Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. Piper Sandler reissued a “neutral” rating and issued a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and increased their price target for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Finally, Guggenheim started coverage on shares of Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Tempus AI has an average rating of “Moderate Buy” and a consensus target price of $56.36.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.